Mucosal immunity to HIV-1: Systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A)

Journal of Immunology

Volumn 157, Issue 1, 1996, Pages 462-472

  Staats, Herman F ^a   Nichols, W Garrett ^b   Palker, Thomas J ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; DELAYED HYPERSENSITIVITY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; INTRANASAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VAGINA SECRETION;

ADMINISTRATION, INTRANASAL; AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; ANTIBODY-PRODUCING CELLS; CHOLERA TOXIN; EPITOPES; FEMALE; HIV ANTIBODIES; HIV ANTIGENS; HIV ENVELOPE PROTEIN GP120; HIV-1; HYPERSENSITIVITY, DELAYED; IMMUNITY, MUCOSAL; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; VAGINA;

EID: 0029999191     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Chin, J. 1991. Global estimates of AIDS cases and HIV infection. AIDS 5(Suppl. 2):S57.
2. Milman, G., and O. Sharma. 1994. Mechanisms of HIV/SIV mucosal transmission. AIDS Res. Hum. Retroviruses 10:1305.
3. Baba, T. W., J. Koch, E. S. Mittler, M. Greene, M. Wyand, D. Penninck, and R. M. Ruprecht. 1994. Mucosal infection of neonatal rhesus monkeys with cell-free SIV. AIDS Res. Hum. Retroviruses 10:351.
4. Charbit, A., P. Marineau, J. Ronce, C. Leclerc, R. Lo-Man, V. Michel, O'Callaghan, and M. Hofnung. 1993. Expression and immunogenicity of the V3 loop from the envelope of human immunodeficiency virus type 1 in an attenuated aroA strain of Salmonella typhimurium upon genetic coupling to two Escherichia coli carrier proteins. Vaccine 11:1221.
5. Natuk, R . J., M . D. Lubeck, P. K. Chanda, M. Chengalvala, M. S. Wade, S. C. S. Murthy, J. Wilhelm, S. K. Vernon, S. K. Dheer, S. Mizutani, S. G. Lee, K. K. Murthy, J. W. Eichberg., A. R. Davis, and P. P. Hung. 1993. Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees. AIDS Res. Hum. Retroviruses 9:395.
6. Johnson, R. P., S. A. Hammond, A. Trocha, R. F. Siliciano, and B. D. Walker. 1994. Induction of a major histocompatibility complex Class I-restricted cytotoxic T-lymphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine. J. Virol. 68:3145.
7. von Brunn, A., M. Brand, C. Reichhuber, C. Morys-Wortman, F. Deinhardt, and F. Schodel. 1993. Principal neutralizing domain of HIV-1 is highly immuongenic when expressed on the surface of hepatitis B core particles. Vaccine 11:817.
8. Fuller, D. H., and J. R. Haynes. 1994. A qualitative progression in HIV type 1 glycoprotein 120-specific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based glycoprotein 120 vaccine. AIDS Res. Hum. Retroviruses 11:1433.
9. Berzofsky, J. A., C. D. Pendleton, M. Clerici, J. Ahlers, D. R. Lucey, S. D. Putney, and G. M. Shearer. 1991. Construction of peptides encompassing multideterminant clusters of human immunodeficiency virus envelope to induce in vitro T cell responses in mice and humans of multiple MHC types. J. Clin. Invest. 88:876.
10. O'Hagan, D T., D. Rafferty, J. A. McKeating, and L. Illum. 1992. Vaginal immunization of rats with a synthetic peptide from human immunodeficiency virus envelope glycoprotein. J. Gen. Virol. 73:2141.
11. Nishino, Y., M. Kameoka, Y. Okada, Q. Zhong, T. Kimura, I. Azuma, and K. Ikula. 1994. In vivo induction of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes and delayed-type hypersensitivity by a 23-amino acid peptide from the highly conserved region in major core protein p24. Vaccine 12:485.
12. Moore, R. L., and B. S. Fox. 1993. Immunization of mice with human immunodeficiency virus glycoprotein gp160 peptide 315-329 induces both class I- and class II-restricted T cells: not all T cells can respond to whole molecule stimulation. AIDS Res. Hum. Retroviruses 9:51.
13. Ahlers, J. D., C. D. Pendleton, N. Dunlop, A. Minassian, P. L. Nara, and J. A. Berzofsky. 1993. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunization. J. Immunol. 150:5647.
14. Wagner, R., S. Modrow, T. Böltz, H. Fließbach, M. Niedrib, A. v. Brunn, and H. Wolf. 1992. Immunological reactivity of a human immunodeficiency virus type I-derived peptide representing a consensus sequence of the gp120 major neutralizing region V3. Arch. Virol. 127:139.
15. Eriksson, K., P. Horal, B. Svenerholm, S. Jeansson, A. Vahlne, J. Holmgren, and C. Czerkinsky. 1990. Systematic identification of T-cell activating epitope on the human immnodefiiency virus type 1 envelope glycoprotein gp120 in primates immunized with synthetic peptides. Vaccine 8:859.
16. Conley, A. J., P. Conard, S. Bondy, C. A. Dolan, J. Hannah, W. J. Leanza, S. Marburg, C. A. Rivetna, V. K. Rusiecki, E. E. Sugg, F. V. Middlesworth, S. A. Warne, J. T. Ulrich, J. A. Rudbach, R. L. Tolman, and E. A. Emini. 1994. Immunogenicity of synthetic HIV-1 gp120 V3-loop peptide-conjugate immunogens. Vaccine 12:445.
17. + CTL in vivo with peptide vaccine constructs. J. Immunol. 152:549.
18. Palker, T. J., M. E. Clark, A. J. Langlois, T. J. Matthews, K. J. Weinhold, R. R. Randall, D. P. Bolognesi, and B. F. Haynes. 1988. Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc. Natl. Acad. Sci. USA 85:1932.
19. Palker, T. J., T. J. Matthews, A. Langlois, M. E. Tanner, M. E. Martin, R. M. Scearce, J. E. Kim, J. A. Berzofsky, D. P. Bolognesi, and B. F. Haynes. 1989. Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes. J. Immunol. 142:3612.
20. Hart, M. K., T. J. Palker, T. J. Matthews, A. J. Langlois, N. W. Lerche, M. E. Martin, R. M. Scearce, C. McDanal, D. P. Bolognesi, and B. F. Haynes. 1990. Synthetic peptides containing T and B cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in rhesus monkeys. J. Immunol. 145:2677.
21. Haynes, B. F., J. V. Torres, A. J. Langlois, D. P. Bolognesi, M. B. Gardner, T. J. Palker, R. M. Scearce, D. M. Jones, M. A. Moody, C. McDanal, and T. J. Matthews. 1993. Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides. J. Immunol. 151:1646.
22. + cytotoxic T cells in vivo by carrier-free HIV synthetic peptides. Proc. Natl. Acad. Sci. USA 88:9448.
23. Lue, C., A. W. L. Van Den Wall Bake, S. J. Prince, B. A. Julian, M.-L. Tseng, J. Radl, C. O. Elson, and J. Mestecky. 1994. Intraperitoneal immunization of human subjects with tetanus toxoid induces specific antibody-secreting cells in the peritoneal cavity and in the circulation, but fails to elicit secretory IgA responses. Clin. Exp. Immunol. 96:356.
24. Lehner, T., L. Tao, C. Panagiotidi, L. S. Klavinskis, R. Brookes, L. Hussain, N. Meyers, S. E. Adams, A. J. H. Gearing, and L. S. Bergmeier. 1994. Mucosal model of genital immunization in male rhesus macaques with a recombinant simian immunodeficiency virus p27 antigen. J. Virol. 68:1624.
25. McDermott, M. R., and J. Bienenstock. 1979. Evidence for a common mucosal immunologic system. I. Migration of B immunoblasts into intestinal, respiratory, and genital tissues. J. Immunol. 122:1892.
26. Kutteh, W. H., and J. Mestecky. 1994. Secretory immunity in the female reproductive tract. Am. J. Reprod. Immunol. 31:40.
27. Perra, M. T., F. Turno, and P. Sirigu. 1994. Human urethral epithelium: immunohistochemical demonstration of secretory IgA. Arch. Androl. 32:227.
28. Lehner, T., L. A. Bergmeier, C. Panagiotidi, L. Tao, R. Brookes, L. S. Klavinskis, P. Walker, J. Walker, R. G. Ward, L. Hussain, A. J. H. Gearing, and S. E. Adams. 1992. Induction of mucosal and systemic immunity to a recombinant simian immunodeficiency viral protein. Science 258:1365.
29. Marx, P. A., R. W. Compans, A. Gettie, J. K. Staas, R. M. Gilley, M. J. Mulligan, G. V. Yamshchikov, D. Chen, and J. H. Eldridge. 1993. Protection against vaginal SIV transmission with microencapsulated vaccine. Science 260:1323.
30. Kiyono, H., J. R. McGhee, M. J. Wannemuehler, M. V. Frangakis, D. M, Spalding, S. M. Michalek, and W. J. Koopman. 1982. In vitro immune responses to a T cell-dependent antigen by cultures of dissassociated murine Peyer's patch. Proc. Natl. Acad. Sci. USA 79:596.
31. Jackson, R. J., K. Fujihashi, J. Xu-Amano, H. Kiyono, and J. R. McGhee. 1993. Optimizing oral vaccines: induction of systemic and mucosal B cell and antibody responses to tetanus toxoid by use of cholera toxin as adjuvant. Infect. Immun. 61:4272.
32. Lausch, R. N., W. R. Kleinschrodt, C. Monteiro, S. G. Kayes, and J. E. Oakes. 1985. Resolution of HSV corneal infection in the absence of delayed-type hypersensitivity. Invest. Ophthalmol. Vis. Sci. 26:1509.
33. Graham, B. S., T. J. Matthews, R. B. Belshe, M. L. Clements, R. Dolin, P. F. Wright, G. J. Gorse, D. H. Schwartz, M. C. Keefer, D. P. Bolognesi, L. Corey, D. M. Stablein, J. R. Esterlitz, S.-L. Hu, G. E. Smith, P. E. Fast, W. C. Koff, and the NIAID AIDS Vaccine Clinical Trials Network. 1993. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. J. Infect. Dis. 167:533.
34. Wild, C., Dubay, J. W., Greenwell, T., Baird, T. Jr., Oas, T. G., McDanal, C., Hunter, E., and Matthews, T. 1994. Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc. Natl. Acad. Sci. USA 91:12676.
35. Clarke, C. J., A. D. Wilson, N. A. Williams, and C. R. Stokes. 1991. Mucosal priming of T-lymphocyte responses to fed protein antigens using cholera toxin as an adjuvant. Immunology 72:323.
36. Homquist, E., and K. Lycke. 1993. Cholera toxin adjuvant greatly promotes antigen priming of T cells. Eur. J. Immunol. 23:2136.
37. Lycke, N., U. Karlsson, A. Sjolander, and K.-E. Magnusson. 1991. The adjuvant action of cholera toxin is associated with an increased intestinal permeability for luminal antigens. Scand. J. Immunol. 33:691.
38. Bromander, A. K., M. Kjerrulf, J. Holmgren, and N. Lycke. 1993. Cholera toxin enhances alloantigen presentation by cultured intestinal epithelial cells. Scand. J. Immunol. 37:454.
39. Snider, D. P., J. S. Marshall, M. H. Perdue, and H. Liang. 1994. Production of IgE antibody and allergic sensitization of intestinal and peripheral tissues after oral immunization with protein antigen and cholera toxin. J. Immunol. 153:647.
40. Fontana, M. R., R. Manetti, V. Giannelli, C. Magagnoli, A. Marchini, R. Olivieri, M. Domenighini, R. Rappuoli, and M. Pizza. 1995. Construction of nontoxic derivatives of cholera toxin and characterization of the immunological response against the A subunit. Infect. Immun. 63:2356.
41. Dickinson, B. L., and J. D. Clements. 1995. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immun. 63:1617.
42. Mossmann, T. R., and R. L. Coffman. 1989. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:145.
43. + T-cell subsets in vivo. Immunol. Rev. 123:189.
44. Xu-Amano, J., R. J. Jackson, H. F. Staats, K. Fujihashi, H. Kiyono, P. D. Burrows, C. O. Elson, S. Pillai, and J. R. McGhee. 1993. Helper T cell subsets for IgA responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues. J. Exp. Med. 178:1309.
45. Marinaro, M., H. F. Staats, H. Kiyono, R. J. Jackson, M . Coste, T. Hiroi, and J. R. McGhee. The adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and cytokines which support IgE responses. J. Immunol. 155:4621.
46. Hirabayashi, Y., H. Kurata, H. Funato, T. Nagamine, C. Aizawa, S. Tamura, K. Shimada, and T. Kurata. 1990. Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination. Vaccine 8:243.
47. Pal, S., T. J. Fielder, E. M. Peterson, and L. M. DE LA Maza. 1994. Protection against infertility in a BALB/c mouse salpingitis model by intranasal immunization with the mouse pneumonitis biovar of Chlamydia trachomatis. Infect. Immun. 62:3354.
48. Katz, J., C. C. Harmon, G. P. Buckner, G. J. Richardson, M. W. Russell, and S. M. Michalek. 1993. Protective salivary immunoglobulin A responses against Streptococcus mutans infection after intranasal immunization with S. mutans antigen I/II coupled to the B subunit of cholera toxin. Infect. Immun. 61:1964.
49. Takahashi, I., N. Okahashi, T. Kanamoto, H. Asakawa, and T. Koga. 1990. Intranasal immunization of mice with recombinant protein antigen of serotype c Streptococcus mutans and cholera toxin B subunit. Arch. Oral Biol. 35:475.
50. Shanin, R. D., D. F. Amsbaugh, and M. F. Leef. 1992. Mucosal immunization with filamentous hemagglutinin protects against Bordetella pertussis respiratory infection. Infect. Immun. 60:1482.
51. Hagansee, M. E., J. J. Carter, G. C. Wipf, and D. A. Galloway. 1995. Immunization of mice with HPV vaccinia virus recombinants generates serum IgG, IgM and mucosal IgA antibodies. Virology 206:174.
52. Mestecky, J., and J. R. McGhee. 1987. Immunoglobulin A (IgA): molecular and cellular interactions involved in IgA biosynthesis and immune response. Adv. Immunol. 40:153.
53. Pal, S. L., T. J. Fielder, E. M. Peterson, and L. M. de la Maza. 1994. Protection against infertility in a BALB/c mouse salpingitis model by intranasal immunization with the mouse pneumonitis biovar of Chlamydia trachomatis. Infect. Immun. 62:3354.
54. Furr, P. M., and D. Taylor-Robinson. 1993. Mycoplasma pulmonis infection of the murine oropharynx protects against subsequent vaginal colonization. Epidemiol. Infect. 111:307.
55. Renegar, K. B., and P. A. Small, Jr. 1991. Passive transfer of local immunity to influenza virus infection by IgA antibody. J. Immunol. 146:1972.
56. Winner, L., III, J. Mack, R. Weltzin, J. J. Mekalanos, J. P. Kraehenbuhl, and M. Neutra. 1991. New model for analysis of mucosal immunity: intestinal secretion of specific monoclonal immunoglobulin A from hybridoma tumors protects against Vibrio cholerae infection. Infect. Immun. 59:977.
57. Michetti, P., M. J. Mahan, J. M. Slauch, J. J. Mekalanos, and M. R. Neutra. 1992. Monoclonal secretory immunoglobulin A protects mice against oral challenge with the invasive pathogen Salmonella typhimurium. Infect. Immun. 60:1786.
58. Czinn, S. J., A. Cai, and J. G. Nedrud. 1993. Protection of germ-free mice from infection by Helicobacter felis after active oral or passive IgA immunization. Vaccine 11:637.
59. Bukawa, H., K. I. Sekigawa, K. Hamajima, J. Fukushima, Y. Yamada, H. Kiyono, and K. Okuda. 1995. Neutralization of HIV-1 by secretory IgA induced by oral immunization with a new macromolecular multicomponent peptide vaccine candidate. Nat. Med. 1:681.
60. Burnett, P. R., T. C. VanCott, V. R. Polonis, R. R. Redfield, and D. L. Birx. 1993. Serum IgA-mediated neutralization of HIV type 1. J. Immunol. 152:4642.
61. Kozlowski, P. A., D. Chen, J. H. Eldridge, and S. Jackson. 1994. Contrasting IgA and IgG neutralizing capacities and response to HIV type 1 gp120 V3 loop in HIV-infected individuals. AIDS Res. Hum. Retroviruses 19:813.
62. Kozlowski, P. A., K. P. Black, L. Shen, and S. Jackson. 1994. High prevalence of serum IgA HIV-1 infection-enhancing antibodies in HIV-infected persons: masking by IgG. J. Immunol. 154:6163.
63. Cichutek, K., H. Merget, S. Norley, R. Linde, W. Kreuz, M. Gahr, and R. Kurth. 1992. Development of aquasispecies of human immunodeficiency virus type 1 in vivo. Proc. Natl. Acad. Sci. USA 89:7365.
64. Kliks, S. C., T. Shioda, N. L. Haigwood, and J. A. Levy. 1993. V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 90:11518.
65. Doel, T. R., C. Gale, C. M. C. F. Do Amaral, G. Mulcahy, and R. DiMarchi. 1990. Heterotypic protection induced by synthetic peptides corresponding to three serotypes of foot-and-mouth disease virus. J. Virol. 64:2260.
66. Harari, I., and R. Arnon. 1990. Carboxyl-terminal peptides from the B subunit of shiga toxin induce a local and parenteral protective effect. Mol. Immunol. 27:613.
67. Schulz, M., R. M. Zinkernagel, and H. Hengartner. 1991. Peptide-induced antiviral protection by cytotoxic T cells. Proc. Natl. Acad. Sci. USA 88:991.
68. Takahashi, I., N. Okahashi, K. Matsushita, M. Tokuda, T. Kanamoto, E. Munekata, M. W. Russel, and T. Koga. 1991. Immunogenicity and protective effect against oral colonization by Streptococcus mutans of synthetic peptides of a streptococcal surface protein antigen. J. Immunol. 146:332.
69. Bessen, D., and V. A. Fischetti. 1990. Synthetic peptide vaccine against mucosal colonization by group A streptococci. I. Protection against a heterologous M serotype with shared C repeat region epitopes. J. Immunol. 145:1251.